- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03025113
Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment
February 23, 2021 updated by: EMS
Phase III, National, Multicenter, Randomized, Double-blind, Double-Masked, Compare the Efficacy of Ketoprofen + Cyclobenzaprine Association Versus Cyclobenzaprine (Miosan®) in the Treatment of Osteomuscular Pain in Adults
The purpose of this study is to evaluate the safety and efficacy of an association with one anti-inflammatory and one muscle relaxant agent compared to the one muscle relaxant agent isolated in the treatment of osteomuscular pain in adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Double-blind, randomized, multicenter
- Maximal experiment duration: 9 days
- 02 or 03 visits and a phone contact
- Evaluate the efficacy of an association with one anti-inflammatory and one muscle relaxant agent compared to the one muscle relaxant agent isolated in the treatment of osteomuscular pain in adults.
- Adverse events evaluation
Study Type
Interventional
Enrollment (Actual)
416
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13.084-791
- Allegisa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
IInclusion Criteria:
- Signed Consent of the patient;
- Participants presenting musculoskeletal pain, moderate or moderately severe, with VAS (visual analog scale) greater than 40 mm for a period of less than seven (7) days.
Exclusion Criteria:
- Patients with any clinically significant disease that in the investigator is opinion can´t participate in the study;
- Patients with any laboratory finding or image finding that in the investigator is opinion can´t participate in the clinical trial;
- Patients with history of hypersensitivity to any of the formula compounds;
- Participation in clinical trial in the year prior to this study;
- Pregnancy or risk of pregnancy and lactating patients;
- Patients who were in use of drugs that can interfere with evaluation;
- History of with rheumatic diseases, fibromyalgia, osteoarticular diseases, dystonia, dystrophies and myopathies, acute infectious diseases, gastric duodenal ulcer or gastritis;
- Renal or hepatic impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EMS association
The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
|
The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
Other Names:
|
Active Comparator: Miosan®
The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
|
The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of osteomuscular treatment based on proportion of participants who achieve the 2, 3 or 4 points in the pain scale.
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety will be evaluated by the adverse events occurrences
Time Frame: Maximal experiment duration: 9 days
|
Maximal experiment duration: 9 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 8, 2018
Primary Completion (Actual)
November 29, 2019
Study Completion (Actual)
March 27, 2020
Study Registration Dates
First Submitted
January 17, 2017
First Submitted That Met QC Criteria
January 17, 2017
First Posted (Estimate)
January 19, 2017
Study Record Updates
Last Update Posted (Actual)
February 24, 2021
Last Update Submitted That Met QC Criteria
February 23, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Musculoskeletal Pain
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Neuromuscular Agents
- Adrenergic Uptake Inhibitors
- Muscle Relaxants, Central
- Amitriptyline
- Ketoprofen
- Cyclobenzaprine
Other Study ID Numbers
- EMS0116
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Pain
-
Sykehuset i Vestfold HFActive, not recruitingBack Pain | Musculoskeletal Pain | Chronic Pain | Musculoskeletal Diseases or Conditions | Pain, Chronic | Musculoskeletal Disorder | Musculoskeletal Neck PainNorway
-
University of Missouri, Kansas CityTerminatedOrthopaedic Related Pain (Musculoskeletal Pain)United States
-
Uppsala UniversityDalarna County Council, Sweden; Center for Clinical Research Dalarna, Sweden; REHSAM, SwedenTerminatedMusculoskeletal Neck Pain | Musculoskeletal Shoulder PainSweden
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Massachusetts General HospitalOrthopaedic Trauma AssociationCompleted
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPain | Joint Pain | Pain, Chronic | Chronic Musculoskeletal PainUnited States
-
University of North Carolina, Chapel HillYale University; Duke University; National Institute on Aging (NIA); Indiana University and other collaboratorsCompletedChronic Pain | Acute Musculoskeletal PainUnited States
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted
-
Wayne State UniversityUniversity of MichiganCompleted
Clinical Trials on ketoprofen and cyclobenzaprine association
-
EMSCompletedMusculoskeletal PainBrazil
-
Institut BergoniéBayerRecruiting
-
EMSRecruitingBenign Prostatic Hyperplasia | Erectile DysfunctionBrazil
-
NorthShore University HealthSystemCompleted
-
Mahidol UniversityCompletedPeriodontal Diseases | MalnutritionThailand
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.Completed
-
ZARS Pharma Inc.CompletedOsteoarthritisUnited States
-
Masaryk UniversitySt. Anne's University Hospital Brno, Czech RepublicNot yet recruitingAlzheimer Disease | Healthy Aging | Mild Cognitive Impairment | Memory Disorders in Old AgeCzechia
-
Helse-Bergen HFUniversity Hospital of North Norway; Helse FordeCompletedDevelopmental Dysplasia of the Hip